shutterstock_17556916_-ouh_desire

Ouh Desire / Shutterstock.com

30 September 2019BiotechnologyRichard Wells and Stephanie Pilkington

Dosage patents: Down the hatch

The Supreme Court judgment on March 27, 2019 in Actavis v ICOS UK concerned ICOS’s EP (UK) 1 173 181, exclusively licensed to Eli Lilly, and found it invalid for lack of inventive step in the face of Actavis’, and others’, revocation challenge.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

Taylor Wessing expands in Europe with Paris team

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Biotech and healthcare expert returns to Latham & Watkins

AstraZeneca to appeal invalidated diabetes patent in generics dispute

Commercialising genomic tech in Nigeria

Why US patent reform is ‘essential’ for US economic prosperity and security